Valneva Reports Positive Final Data for IXCHIQ Vaccine

Valneva announced "positive" final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ, in 304 children, twelve months after vaccination. Final VLA1553-221 results aligned with the initial data and six-month outcomes that the company previously reported for this trial in January 2025 and June 2025, respectively, the company stated. The strong immune response was confirmed in CHIKV-naive children with a 94.7% seroresponse rate at Day 360. The vaccine was well tolerated in children aged one to eleven years regardless of the dose or previous CHIKV infection. No safety concerns were identified. Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, "The twelve months persistence and safety data in children are consistent with the robust antibody response and favorable safety profile previously observed in adolescents following a single vaccination. As safety is of the utmost importance, particularly when advancing into a Phase 3 pediatric study, we have decided, in alignment with the regulatory authorities, to continue gathering additional real-world experience in the adolescent population before initiating our planned Phase 3 study in children. We remain convinced, considering the significant risk chikungunya poses to individuals living in or traveling to endemic areas, that it is crucial to ensure a vaccine capable of potentially offering long-term protection from a single shot is accessible to people of all ages. This is especially important in Low- and Middle-Income countries where access to vaccines is often limited."